临床试验中炎症性肠病活动的内镜评估
在克罗恩病和溃疡性结肠炎中,症状与活动性管腔炎症相关性差,因此领域转向使用内镜评估炎症活动。多种内镜指数被使用但均未完全验证,其中CD的SES-CD和CDEIS最常用但存在评分复杂、狭窄等项目可靠性差等局限;UC的Mayo内镜子评分是监管标准,UCEIS可能提供更精细评估。PRO与内镜联合结局受监管机构青睐但需进一步验证。
要点
- 症状与活动性管腔炎症相关性差,内镜评估是临床试验中评价IBD活动的重要工具。
- SES-CD和CDEIS最常用于CD但未完全验证,评分复杂且狭窄等项目可靠性差。
- UC中Mayo内镜子评分为监管标准,UCEIS可能提供更精细的疾病活动评估。
核心结论
- 内镜评估已用于IBD临床试验中评价炎症活动,但现有内镜指数均未完全验证,联合PRO与内镜的结局需进一步验证。
研究设计与样本
- 本文为综述,描述临床试验中内镜评估的指征、最常用的内镜指数及未来评估方向。
主要发现
- CD中SES-CD和CDEIS最常用,但除验证不完整外,存在评分复杂和狭窄等项目可靠性差的局限。
- CD术后Rutgeerts评分主要作为预后而非评估工具,也需额外验证。
- UC中Mayo内镜子评分被用作监管标准,UCEIS可能提供对疾病活动各组分更精细的评估。
- 联合PRO与内镜指数的复合结局受监管机构青睐,但需进一步验证。
临床怎么用
- 临床试验中评价IBD活动应优先采用内镜评估,而非仅依赖症状。
- 选择内镜指数时需考虑其验证状态和局限性,如SES-CD/CDEIS评分复杂、狭窄项目可靠性差。
- UC监管终点可采用Mayo内镜子评分,UCEIS可用于更精细的组分评估。
- PRO与内镜联合结局可用于监管目的,但需注意其尚需进一步验证。
局限性
- 现有内镜指数均未完全验证,部分指数存在评分复杂和项目可靠性差的问题。
- Rutgeerts评分主要作为预后工具,用于评估需额外验证。
- PRO与内镜联合结局需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with Crohn's disease and ulcerative colitis, poor correlation between symptoms and active luminal inflammation has been well established. As a result, the field has moved towards the use of endoscopic assessment to evaluate inflammatory activity. Numerous endoscopic indices have been used for this purpose although none are completely validated. The Simple Endoscopic Score for Crohn's Disease and the Crohn's Disease Endoscopic Index of Severity have been used most frequently; however in addition to incomplete validation, they have important limitations for clinical use, including complexity of scoring and poor reliability of items such as stenosis. The Rutgeerts' score for postoperative Crohn's disease was developed primarily as a prognostic rather than evaluative tool and also requires additional validation. In ulcerative colitis, the Mayo endoscopic subscore has been used as the regulatory standard, although the Ulcerative Colitis Endoscopic Index of Severity may provide a more granular assessment of individual components of disease activity. The use of combined outcomes with patient reported outcomes (PROs) and endoscopic indices has received favor by regulatory bodies but require further validation. This review describes the indications for endoscopic assessment in trials, the indices most frequently utilized for these purposes, and potential future approaches to assessment of disease activity.
引用
- Khanna R, Ma C, Jairath V, et al. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol. 2020. PMID: 33338657. doi:10.1016/j.cgh.2020.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。